Prosecution Insights
Prosecution Insights
Tech Center 3600 • Art Units: 1621 1624 3646
This examiner grants 65% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17911022 | 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 17497633 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | Final Rejection | Hoffmann-La Roche Inc. |
| 18251101 | CRYSTALLINE FORM II OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR | Final Rejection | LG CHEM, LTD. |
| 18022962 | MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF | Final Rejection | Massachusetts Institute of Technology |
| 18559017 | N-ACYL FOSMIDOMYCIN PRODRUG ANALOGS AS NOVEL ANTIINFECTIVE AGENTS | Non-Final OA | THE GEORGE WASHINGTON UNIVERSITY |
| 17906580 | FARNESOID X RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASE | Non-Final OA | ELI LILLY AND COMPANY |
| 18262429 | METHOD FOR THE CONTROL OR SUPPRESSION OF PHYTOPATHOGENIC BACTERIA | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18546322 | RADIOLABELED COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | The Research Foundation for the State University of New York |
| 18035429 | APPLICATION OF ISOQUINOLINE COMPOUND IN TUMOR TREATMENT | Non-Final OA | TONGJI UNIVERSITY |
| 17597166 | IRAK DEGRADERS AND USES THEREOF | Final Rejection | Kymera Therapeutics, Inc. |
| 18577261 | COMPOUND USED AS SHP2 INHIBITOR AND USE THEREOF | Non-Final OA | TYK MEDICINES (ZHENGZHOU), INC. |
| 18256091 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Non-Final OA | Erasca, Inc. |
| 18027313 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Final Rejection | Erasca, Inc. |
| 18568761 | COMPOUND AS CDK KINASE INHIBITOR AND USE THEREOF | Non-Final OA | TYK MEDICINES, INC. |
| 18568686 | METHODS AND COMPOSITIONS FOR LIPID FORMULATION OF LIPOPHILIC SMALL MOLECULE THERAPIES OF THE HETEROCYCLIC TYPE | Non-Final OA | Neuronascent, Inc. |
| 18568448 | COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-RELATED GASTROINTESTINAL SIDE EFFECTS | Non-Final OA | ONQUALITY PHARMACEUTICALS CHINA LTD. |
| 18563275 | INSECT REPELLANT FORMULATION AND METHOD OF USING SAME | Non-Final OA | ROSS LIFESCIENCE PRIVATE LIMITED |
| 18559020 | COMPOSITION COMPRISING PPAR-MODULATOR AND AN UROLITHIN DERIVATIVE AND USES THEREOF | Non-Final OA | Institut National de la Santé et de la Recherche Médicale - INSERM |
| 18373906 | TREATMENT OF MENTAL DISORDERS | Non-Final OA | GH Research Ireland Limited |
| 17641813 | DNA-PK INHIBITING COMPOUNDS | Non-Final OA | Provincial Health Services Authority |
| 18039644 | CARBONIC ANHYDRASE INHIBITORS SYNTHESIZED ON INTERCONNECTING LINKER CHAINS | Non-Final OA | VILNIUS UNIVERSITY |
| 18452606 | AGAROFURAN COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Non-Final OA | BEIJING CHY PHARMACEUTICAL TECHNOLOGY CO, LTD. |
| 18015445 | POLYMORPHS OF A GABAA ALPHA5 AGONIST AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT | Non-Final OA | AGENEBIO, INC. |
| 18042485 | COMBINATION OF CABOTEGRAVIR AND LEVONORGESTREL | Non-Final OA | ViiV Healthcare Company |
| 18275382 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | Non-Final OA | Triana Biomedicines, Inc. |
| 18263059 | IMMUNOSUPPRESSIVE PHARMACEUTICAL COMPOSITION INCLUDING BENZENE DERIVATIVE AS IMMUNOSUPPRESSANT | Final Rejection | PROVIBIO CO., LTD. |
| 18266199 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Non-Final OA | NOVARTIS PHARMA AG |
| 18255205 | PHARMACEUTICAL COMBINATION OF A CORTICOSTEROID AND AN ANTIHISTAMINE FOR THE TREATMENT AND CONTROL OF THE INFLAMMATORY COMPONENT OF ALLERGIC PROCESSES | Final Rejection | LABORATORIOS SILANES S.A. DE C.V. |
| 18311850 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Final Rejection | Kumquat Biosciences Inc. |
| 18251501 | Compounds | Final Rejection | University Court of the University of St Andrews |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy